4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy’s phase 3 plans
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in upfront cash to fund the asset’s phase 3 development. In…